AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03146832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy (according to habituation approach)
Description: Exposure instruction focuses on fear reduction during exposure sessions
Study NCT03146832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy (according to inhibitory learning approach)
Description: Exposure instruction focuses on expectation violation during exposure sessions
Study NCT02724813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Preformance (COOP)
Study NCT02724813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Orientation to Occupational Preformance (COOP)
Study NCT00494260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Learning and Cognitive Behavioral Therapy (SLCBT)
Description: The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
Study NCT00494260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Support (ES)
Description: The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
Study NCT02900612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water aerobics training.
Description: The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
Study NCT02900612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water resistance training.
Description: The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Study NCT02900612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Study NCT03709290 — intervention group
Intervention type: RADIATION
Intervention: mri
Description: mri brain \& spinal cord
Study NCT05165953 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there was no intervention in the study
Study NCT01657630 — intervention group
Intervention type: DEVICE
Intervention: Accu-Chek Combo System
Description: 12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
Study NCT03472573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03472573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02566070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Gastric Feeding
Study NCT02566070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus Gastric Feeding
Study NCT02442635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
Study NCT00478439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ZeaVision EyePromise Restore
Description: Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
Study NCT00739895 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac magnetic Resonance study
Description: follow-up studies
Study NCT00739895 — intervention group
Intervention type: PROCEDURE
Intervention: Blood testing
Description: Blood sample tested for myocardial biomarkers
Study NCT04542226 — intervention group
Intervention type: DRUG
Intervention: Polyoxidonium
Description: Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
Study NCT00478439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin
Description: Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
Study NCT02751645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic hemodilution
Description: ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
Study NCT02062281 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
Study NCT02062281 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent influenza vaccine
Description: Single 0.5ml trivalent influenza vaccine was administered IM
Study NCT02062281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23vPPV+TIV
Description: Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
Study NCT04589390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Selexipag
Description: treatment with selexipag
Study NCT01150019 — intervention group
Intervention type: OTHER
Intervention: Cross sectional study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
Study NCT03198936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cognizin® SynapsaTM
Description: 2 capsules to be taken twice a day with meals with a glassful of water
Study NCT03198936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules to be taken twice a day with meals with glassful of water
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: 125 mg QD orally every day
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 125 mg QD orally every day
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study NCT00460317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study NCT03068013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Description: CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
Study NCT03068013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPI
Description: Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
Study NCT00005881 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Forms
Description: Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
Study NCT03719053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
Study NCT03066622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care as per attending physician
Description: Patients are randomized to standard of care medication (as determined by attending physician)
Study NCT03066622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg rapidly dissolving olanzapine
Description: 5mg rapidly dissolving olanzapine
Study NCT03380793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morinidazole
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
Study NCT02916797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping training with feedback
Description: Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
Study NCT03486925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (24IU)
Study NCT03486925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo
Study NCT03539367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study NCT03539367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study NCT01598402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid suspension
Description: 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
Study NCT03983993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT03983993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT00860067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV (MEDI3250)
Description: 0.2 mL dose at Day 0
Study NCT00860067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Yamagata
Description: 0.2 mL dose at Day 0
Study NCT00860067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Victoria
Description: 0.2 mL dose at Day 0
Study NCT01316341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
Study NCT01316341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patient to receive two placebos
Study NCT01316341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patient to receive two placebos
Study NCT01316341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
Study NCT02289547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: maintenance capecitabine therapy after six cycles of XELOX
Study NCT04745494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OT administration
Description: OT nasal administration
Study NCT04745494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo nasal administration
Study NCT04822480 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diabetes Prevention Program (DPP)
Description: Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
Study NCT02756832 — intervention group
Intervention type: DRUG
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets
Study NCT00310323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 0.5 mg/kg (maximum 30 mg)
Study NCT00310323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Administered as 4 ounces of Coca-Cola
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Study NCT01540565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01540565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT02724722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned intervention
Description: a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
Study NCT02724722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
Study NCT01115985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT01115985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral
Study NCT03548116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
Study NCT03548116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Study NCT00920621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 cholecalciferol
Description: Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
Study NCT00920621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 IU of vitamin D3 administered orally once a day during pregnancy
Study NCT00920621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 4000 IU of vitamin D3 administered orally once a day during pregnancy
Study NCT01222468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nabilone 0.5 mg
Description: nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
Study NCT01222468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
Study NCT04386226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ambrotose LIFE
Description: Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2，IV, d0
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50 mg/m2/day CI24h d1-d4
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 10 mg/m2/day CI24h d1-d4
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 0.4mg/m2/day CI24h d1-d4
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2/day IV d5
Study NCT04432714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m2/bid oral or IV d1-d5
Study NCT02894125 — intervention group
Intervention type: OTHER
Intervention: SPA Therapy
Study NCT04303026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 5mg IV infusion
Study NCT04303026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Placebo Group. Saline 0.9% 100 ml infusion
Study NCT03580109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
Study NCT03580109 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Late spa treatment
Description: Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
Study NCT02180295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 1
Description: Inactivated Varicella Zoster Virus vaccine
Study NCT02180295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 2
Description: Inactivated Varicella Zoster Virus vaccine
Study NCT02180295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 3
Description: Inactivated Varicella Zoster Virus vaccine
Study NCT05524896 — intervention group
Intervention type: DEVICE
Intervention: ElucidVivo
Description: Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
Study NCT01023256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 0.3 mg/kg or placebo iv x 4 doses
Study NCT01023256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 1.0 mg/kg or placebo iv x 4 doses
Study NCT01023256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 1.5 mg/kg or placebo iv x 4 doses
Study NCT03177031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stay Safe Link (SSL)
Description: CAPD system produced in Malaysia by Fresenius Medical Care
Study NCT03177031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stay Safe (STS)
Description: CAPD system produce in Germany by Fresenius Medical Care
Study NCT04092673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT226
Description: eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
Study NCT04092673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Recommended dosage: 960 mg orally once daily
Study NCT04092673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
Study NCT04092673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Dose in combination with fulvestrant: 150 mg twice daily
Study NCT04092673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg every 3 weeks